At Blank Rome’s 9th Annual State of the Cannabis Industry Conference, Frank A. Segall, partner and co-chair of the firm’s Cannabis practice, asked a panel—including Joseph Andreae, CEO of CULTA, Jared Maloof, CEO of Standard Wellness, Ed Schmults, CEO of Firelands Scientific, and Jim Scott, CEO of Statehouse Holdings—what is the number one issue confronting the cannabis industry today? All four chief executives unanimously echoed the same sentiment: the number one issue confronting state-regulated cannabis operators today is the unregulated hemp market, which has become a growing thorn in their sides as the hemp market picked up steam over the past few years. Well, with new action by lawmakers yesterday, it appears this issue is on the brink of being resolved!
Over the past six years, the hemp industry has transformed from a niche agricultural sector into a national marketplace for diverse cannabinoid products. That transformation was catalyzed by the 2018 Farm Bill, which legalized hemp by defining it as cannabis with no more than 0.3 percent delta-9 tetrahydrocannabinol (“THC”) on a dry-weight basis. What resulted from this was an unintended market: intoxicating hemp-derived cannabinoids such as delta-8 THC, delta-10 THC, and other analogs produced from cannabidiol (“CBD”) isolates through chemical conversion. The “hemp loophole,” as it came to be known, allowed psychoactive products to proliferate in convenience stores, restaurants, and online and circumvented the strict controls applied to state-licensed cannabis.
Yesterday’s news that lawmakers have moved to close that loophole marks a significant regulatory inflection point. While the text and timing of final legislative action will determine the specifics, the thrust is clear: Congress and regulators are converging on a more comprehensive, intoxicant-focused framework that treats all THC variants—and certain synthetic or semi-synthetic cannabinoids—within a unified compliance regime, rather than focusing exclusively on delta-9 THC in the plant as harvested.
How We Got Here
The 2018 Farm Bill’s definition of hemp created bright-line legality around delta-9 THC content but did not address other THC isomers or derivatives that can be made from hemp-derived CBD. That omission enabled widespread production and sale of delta-8 THC and similar compounds, often in edible or vape form, which can deliver psychoactive effects comparable to traditional marijuana products. Because these items were marketed as “hemp,” they entered retail channels with far fewer barriers than state-regulated cannabis—frequently without robust age gating, testing standards, packaging controls, or retail licensure.
State legislatures and courts moved first to contain the issue. Many states enacted strict total-THC limits, imposed age restrictions, banned certain products outright, or required intoxicating hemp items to be sold only through licensed cannabis programs. Courts, in turn, consistently recognized that the Farm Bill does not preempt stricter state rules, reinforcing the principle that states can adopt heightened protections and controls. Federal health authorities also raised alarms about youth access, accidental ingestion, mislabeled potency, and adverse events, intensifying pressure for a federal fix.
Hemp vs. State-Regulated Cannabis
Exploiting the 2018 Farm Bill loophole has created direct competitive pressure on state-regulated cannabis operators. Intoxicating hemp products can be priced lower and are often untaxed and subject to far lighter excise burdens. Hemp products are sold in more outlets with broader hours, and advertised with fewer constraints. Retailers leveraged familiar formats (gummies, vapes, beverages) and potency claims comparable to licensed THC products, siphoning demand from state-regulated dispensaries, depressing customer spend, and otherwise complicating an already complex and delicate market. Hemp brands were able to exploit cross-state distribution without the licensing, seed-to-sale tracking, or vertical-integration limits that define state-regulated cannabis operators, which enabled rapid market penetration for hemp manufacturers and producers. The result was consumer substitution and confusion between “hemp” and “cannabis,” blurring category lines and eroding the competitive position of compliant, taxed operators.
New regulations regarding hemp-derived products are expected to recognize and regulate all psychoactive THC isomers as opposed to solely delta-9 THC in the plant itself, regardless of whether they are naturally occurring in hemp or produced through conversion from CBD. Additionally, federally regulated extraction and synthesis methods will establish permissible extraction processes to make products safer and more transparent. Age restrictions, labeling and testing standards, packaging requirements, and retail channel limitations for intoxicating hemp products are expected to be imposed to protect consumers and reduce youth exposure.
Implications for Industry and Consumers
For manufacturers and retailers, the near-term impact will be operational and strategic. Companies centered on delta-8 and similar products should anticipate tightened compliance requirements, from ingredient sourcing and conversion protocols to lab testing, certifications, and distribution. Some products could shift out of general retail into licensed channels or face outright exclusion if they cannot meet new definitions or safety standards. Conversely, producers who focus on non-intoxicating hemp derivatives—like CBD for topical use or minor cannabinoids without psychoactive effects—could benefit from clearer rules and improved consumer confidence. The result of this loophole closure is likely to be largely disruptive on a $20 billion industry.
For consumers, the changes target transparency and safety. Expect more consistent labeling, verified potency, and access controls designed to keep intoxicating products out of the hands of minors. While availability may narrow in certain retail environments, the overall market should become more reliable and better regulated, reducing the risk of mislabeling or contamination.
What to Watch Next
Manufacturers, retailers, and consumers alike must wait for further regulation in this market to determine the next steps. Transitional provisions—grace periods, grandfathering, and enforcement timelines—will shape how quickly the market adjusts. Federal agencies such as U.S. Food and Drug Administration and U.S. Department of Agriculture will need to make critical decisions regarding product standards, testing, and labeling, all of which could deliver the consistency that has been lacking since 2018.
Bottom Line
Closing the hemp loophole aligns federal law with the reality of a modern cannabinoid marketplace. By regulating intoxication rather than a single THC molecule, Congress is poised to bring clarity where ambiguity has fueled risk, inconsistency, and legal friction. For the hemp industry, the path forward is more rigorous but also more sustainable: a market where non-intoxicating products can thrive under clear rules, and intoxicating products are governed by safeguards proportionate to their effects. For consumers and communities, the result should be safer products, fewer surprises at the point of sale, and a regulatory framework that reflects both innovation and responsibility. Lastly, for state-regulated cannabis operators, the loophole closure comes as a windfall by decreasing direct competitive pressure on state-regulated cannabis operators and giving a much-needed boost to the distressed cannabis industry.
Blank Rome’s cannabis team can assist hemp and cannabis operators in understanding and interpreting the impact of new regulations regarding hemp, as well as help assess the best processes and strategies that can be used to navigate the effects of these proposed developments.
We will continue to closely monitor further regulation as they relate to the sale of hemp and closure of the “hemp loophole” and any subsequent releases of new laws or information from the state and federal regulators on this topic.
[View source.]
